Veritas Pharma Stock Buy Hold or Sell Recommendation

VRTHF Stock  USD 0  0.00  0.00%   
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Veritas Pharma is 'Strong Sell'. Macroaxis provides Veritas Pharma buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding VRTHF positions.
  
Check out Veritas Pharma Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
Note, we conduct extensive research on individual companies such as Veritas and provide practical buy, sell, or hold advice based on investors' constraints. Veritas Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate.

Execute Veritas Pharma Buy or Sell Advice

The Veritas recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Veritas Pharma. Macroaxis does not own or have any residual interests in Veritas Pharma or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Veritas Pharma's advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Veritas PharmaBuy Veritas Pharma
Not Rated
For the selected time horizon Veritas Pharma has a Return On Equity of -5.67, Return On Asset of -0.21, Current Valuation of 1.77 M, Shares Outstanding of 71.14 M, Shares Owned By Insiders of 27.34 % and Price To Earning of 0.20 X
We provide advice to complement the current expert consensus on Veritas Pharma. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time. To make sure Veritas Pharma is not overpriced, please validate all Veritas Pharma fundamentals, including its current ratio, as well as the relationship between the number of employees and net asset . As Veritas Pharma appears to be a penny stock we also recommend to double-check its price to earning numbers.

Veritas Pharma Trading Alerts and Improvement Suggestions

Veritas Pharma generated a negative expected return over the last 90 days
Veritas Pharma has some characteristics of a very speculative penny stock
Veritas Pharma has high likelihood to experience some financial distress in the next 2 years
Veritas Pharma has accumulated 765.63 K in total debt with debt to equity ratio (D/E) of 0.05, which may suggest the company is not taking enough advantage from borrowing. Veritas Pharma has a current ratio of 0.63, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Veritas Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Veritas Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Veritas Pharma sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Veritas to invest in growth at high rates of return. When we think about Veritas Pharma's use of debt, we should always consider it together with cash and equity.
Net Loss for the year was (2.29 M) with loss before overhead, payroll, taxes, and interest of (112.96 K).
Veritas Pharma has accumulated about 125.27 K in cash with (294.86 K) of positive cash flow from operations.
Roughly 27.0% of Veritas Pharma outstanding shares are owned by insiders

Veritas Pharma Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Veritas Pharma or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Veritas Pharma's price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Veritas pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over Dow Jones
0.00
β
Beta against Dow Jones0.00
σ
Overall volatility
0.00
Ir
Information ratio 0.00

Veritas Pharma Volatility Alert

At this time Veritas Pharma exhibits very low volatility. Veritas Pharma is a penny stock. Even though Veritas Pharma may be a good instrument to invest, many penny pink sheets are speculative instruments that are subject to artificial stock promotions. Please make sure you fully understand upside and downside scenarios of investing in Veritas Pharma or similar risky assets. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings,sudden promotions and many other similar artificial hype indicators. We also encourage traders to check work history of company executives before investing in high-volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Veritas instrument if you perfectly time your entry and exit. However, remember that penny pink sheets that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.

Veritas Pharma Fundamentals Vs Peers

Comparing Veritas Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Veritas Pharma's direct or indirect competition across all of the common fundamentals between Veritas Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Veritas Pharma or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Veritas Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Veritas Pharma by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Veritas Pharma to competition
FundamentalsVeritas PharmaPeer Average
Return On Equity-5.67-0.31
Return On Asset-0.21-0.14
Current Valuation1.77 M16.62 B
Shares Outstanding71.14 M571.82 M
Shares Owned By Insiders27.34 %10.09 %
Price To Earning0.20 X28.72 X
Price To Book0.43 X9.51 X
Gross Profit(112.96 K)27.38 B
EBITDA(491.67 K)3.9 B
Net Income(2.29 M)570.98 M
Cash And Equivalents125.27 K2.7 B
Total Debt765.63 K5.32 B
Debt To Equity0.05 %48.70 %
Current Ratio0.64 X2.16 X
Book Value Per Share(0.04) X1.93 K
Cash Flow From Operations(294.86 K)971.22 M
Earnings Per Share(0.03) X3.12 X
Number Of Employees218.84 K
Beta-0.0588-0.15
Market Capitalization1.59 M19.03 B
Total Asset73029.47 B
Net Asset730

Veritas Pharma Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Veritas . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Veritas Pharma Buy or Sell Advice

When is the right time to buy or sell Veritas Pharma? Buying financial instruments such as Veritas Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having Veritas Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Penny Thematic Idea Now

Penny
Penny Theme
Solid stocks, funds or ETFs with below average market capitalization and typicl daily price below 2. The Penny theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Penny Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Veritas Pink Sheet

Veritas Pharma financial ratios help investors to determine whether Veritas Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Veritas with respect to the benefits of owning Veritas Pharma security.